01Histology and lineage
Source-tissue and PDO histology and markers
H&E, Nestin, OLIG2 and S100B place tumor-tissue and PDO lineage context side by side.
Establishes the model-identity baseline for treatment and mechanism studiesStudy resultsCase study
Glioma PDO 2.0: tissue, lineage and functional profiling
Explore glioma PDO 2.0 through histology, lineage markers, CD31 and treatment-response studies.
01Study objective02Model & design03Assays & findings04Decision & next step
Model & sampleTwo glioma PDO 2.0 studies
ObjectiveAssess model identity, vascular context and treatment response across complementary glioma PDO 2.0 studies
Study setupGBM identity profiling with complementary glioma treatment studies
AssaysIdentity profiling: H&E, Nestin, OLIG2 and S100B; complementary studies: CD31, early-apoptosis and necrosis readouts
Study evidenceTwo TRiCBIO glioma PDO 2.0 study datasets
DeliverablesDeliverables are defined by the study scope and may include images, assay results, an analysis summary, methods and a study report
STUDY EVIDENCE
Model identity, vascular context and treatment response
Complementary glioma PDO 2.0 studies separately show model identity and lineage profiling, CD31-associated context and treatment-response readouts.
02Vascular profiling
H&E and CD31 staining in glioma PDO 2.0
A complementary glioma study extends the vascular context through tissue/PDO morphology and CD31-associated profiling.
Helps define spatial, vascular and follow-on mechanism endpoints03Treatment response
Early apoptosis and necrosis under treatment
A complementary study uses early-apoptosis and necrosis readouts to show functional changes across treatment concentrations.
Informs mechanism studies, replication and work in additional samples
INTERPRETATION
Connect lineage, vascular context and functional response
Helps define model-identity, vascular, treatment and mechanism endpoints.
GBM identity profiling and complementary glioma treatment-response data separately show histology, vascular and functional endpoints that can be selected around the sample and model.
Add dose and time-course studies informed by molecular context, followed by mechanism endpoints and independent-model validation.
Related models and services
Choose the right models and services for the next study
PROJECT DISCUSSION
Discuss a study built around your program
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.